OSE Immunotherapeutics Receives €5.2 M in Public Funding for the Clinical Development of …,

This trial is based on robust preclinical data and the recent results from CoVepiT 1, a human ex vivo study which resulted in the identification of immuno- …, This trial is based on robust preclinical data and the recent results from CoVepiT 1, a human ex vivo study which resulted in the identification of immuno- …, Read More

Scroll to Top